Literature DB >> 9560343

Identification of a ligand for the death-domain-containing receptor Apo3.

S A Marsters1, J P Sheridan, R M Pitti, J Brush, A Goddard, A Ashkenazi.   

Abstract

The tumor necrosis factor (TNF) cytokine family regulates development and function of the immune system [1]. TNF is expressed primarily by activated lymphocytes and macrophages and induces gene transcription or apoptosis in target cells [2,3]. We have identified a novel relative of TNF that binds to the recently discovered, death-domain-containing receptor called Apo3 [4] (also known as DR3, WSL-1, TRAMP or LARD [5-9]). The Apo3 ligand (Apo3L) is a 249 amino-acid, type II transmembrane protein. The extracellular sequence of Apo3L shows highest identity to that of TNF. We detected Apo3L mRNA in many human tissues and mapped its encoding gene to chromosome 17p13, near the p53 tumor-suppressor gene. Soluble Apo3L induced apoptosis and nuclear factor kappaB (NF-kappaB) activation in human cell lines. Caspase inhibitors blocked apoptosis induction by Apo3L, as did a dominant-negative mutant of the cell death adaptor protein Fas-associated death domain protein (FADD/MORT1), which is critical for apoptosis induction by TNF [3]. Dominant-negative mutants of several factors that play a key role in NF-kappaB induction by TNF [10] inhibited NF-kappaB activation by Apo3L. Thus, Apo3L has overlapping signaling functions with TNF, but displays a much wider tissue distribution.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9560343     DOI: 10.1016/s0960-9822(98)70204-0

Source DB:  PubMed          Journal:  Curr Biol        ISSN: 0960-9822            Impact factor:   10.834


  37 in total

Review 1.  Signal transduction by tumour necrosis factor and tumour necrosis factor related ligands and their receptors.

Authors:  B G Darnay; B B Aggarwal
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment.

Authors:  Hilary F Clark; Austin L Gurney; Evangeline Abaya; Kevin Baker; Daryl Baldwin; Jennifer Brush; Jian Chen; Bernard Chow; Clarissa Chui; Craig Crowley; Bridget Currell; Bethanne Deuel; Patrick Dowd; Dan Eaton; Jessica Foster; Christopher Grimaldi; Qimin Gu; Philip E Hass; Sherry Heldens; Arthur Huang; Hok Seon Kim; Laura Klimowski; Yisheng Jin; Stephanie Johnson; James Lee; Lhney Lewis; Dongzhou Liao; Melanie Mark; Edward Robbie; Celina Sanchez; Jill Schoenfeld; Somasekar Seshagiri; Laura Simmons; Jennifer Singh; Victoria Smith; Jeremy Stinson; Alicia Vagts; Richard Vandlen; Colin Watanabe; David Wieand; Kathryn Woods; Ming-Hong Xie; Daniel Yansura; Sothy Yi; Guoying Yu; Jean Yuan; Min Zhang; Zemin Zhang; Audrey Goddard; William I Wood; Paul Godowski; Alane Gray
Journal:  Genome Res       Date:  2003-09-15       Impact factor: 9.043

3.  On death receptor 3 and its ligands….

Authors:  Eddie C Y Wang
Journal:  Immunology       Date:  2012-09       Impact factor: 7.397

Review 4.  The TWEAK-Fn14 system as a potential drug target.

Authors:  Harald Wajant
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

Review 5.  TWEAK as a target for therapy in systemic lupus erythematosus.

Authors:  Rui-Xue Leng; Hai-Feng Pan; Wei-Zi Qin; Chao Wang; Li-Li Chen; Jin-Hui Tao; Dong-Qing Ye
Journal:  Mol Biol Rep       Date:  2010-04-01       Impact factor: 2.316

6.  DR3 regulates negative selection during thymocyte development.

Authors:  E C Wang; A Thern; A Denzel; J Kitson; S N Farrow; M J Owen
Journal:  Mol Cell Biol       Date:  2001-05       Impact factor: 4.272

Review 7.  TNF superfamily: a growing saga of kidney injury modulators.

Authors:  Maria D Sanchez-Niño; Alberto Benito-Martin; Sara Gonçalves; Ana B Sanz; Alvaro C Ucero; Maria C Izquierdo; Adrian M Ramos; Sergio Berzal; Rafael Selgas; Marta Ruiz-Ortega; Jesus Egido; Alberto Ortiz
Journal:  Mediators Inflamm       Date:  2010-10-04       Impact factor: 4.711

8.  Apoptosis in autoimmune diabetes: the fate of beta-cells in the cleft between life and death.

Authors:  Charles Sia; Arno Hänninen
Journal:  Rev Diabet Stud       Date:  2006-05-10

9.  APRIL-deficient mice have normal immune system development.

Authors:  Eugene Varfolomeev; Frank Kischkel; Flavius Martin; Dhaya Seshasayee; Hua Wang; David Lawrence; Christine Olsson; Lucrece Tom; Sharon Erickson; Dorothy French; Peter Schow; Iqbal S Grewal; Avi Ashkenazi
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

Review 10.  What can we learn about stroke from retinal ischemia models?

Authors:  Philippe M D'Onofrio; Paulo D Koeberle
Journal:  Acta Pharmacol Sin       Date:  2012-12-03       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.